9/15
08:06 am
btai
BioXcel Therapeutics (NASDAQ:BTAI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
BioXcel Therapeutics (NASDAQ:BTAI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/12
07:56 am
btai
Rating for BTAI
Medium
Report
Rating for BTAI
9/12
07:56 am
btai
Rating for BTAI
Medium
Report
Rating for BTAI